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Abstract
Despite current therapeutic approaches asthma remains uncontrolled in a significant proportion of patients.
Short-acting anticholinergic bronchodilators have a very long history of use in asthma, and recent data confirms
the importance of acetylcholine as both a bronchoconstrictor and as a regulator of inflammation and remodeling
in the lungs. Data from a comprehensive clinical trial programme, as well as use in primary care, show the efficacy
and safety of tiotropium in adults with mild to moderate asthma when it is added to ICS and in severe asthma
when it is added to high doses of ICS plus LABA, as well as in adolescents. Tiotropium is cost effective and its benefits
are not restricted to particular phenotypes, making it a useful addition to the therapeutic options recommended by
the Global Initiative for Asthma (GINA) for people with poorly controlled asthma at steps 4 & 5.
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Background
Asthma remains a major challenge for individuals and
heath service. It affects approximately 235 million people
worldwide [1] and is reported to be the most common
chronic disease in children, affecting 10 % of children
aged 12–18 years in the USA [2]. Current guidelines
emphasize the importance of effective treatment for
achieving and maintaining control. Asthma control con-
sists of 2 domains: current impairment or day-to-day
asthma control (absence of symptoms, minimal reliever
use, and normal activity levels and lung function) and
control of future risk (absence of exacerbations, preven-
tion of decline in lung function, and absence of side ef-
fects from drugs) [3, 4].
Despite major advances in the management of asthma
made in the 1970s with the introduction of inhaled cor-
ticosteroids (ICS) and again in the 1980s with the intro-
duction of long-acting beta agonists (LABA) [5]; and
with the development of national and international man-
agement guidelines [1, 2], many patients, including chil-
dren and adolescents remain uncontrolled and remain at
risk of exacerbations [6–8]. In 2011, the Innovative
Medicine Initiative (IMI) proposed that these patients
should be divided into those with “difficult-to-control
asthma” and those with “severe refractory asthma.” [9].
Difficult to control asthma may be due to a number of
reasons including: confounding illnesses, incorrect
choice of inhaler or poor inhaler technique, concurrent
smoking, uncontrolled rhinitis and non-adherence, ei-
ther intentional or unintentional [10, 11]. Whereas
people with severe refractory asthma have poor asthma
control or frequent severe exacerbations per year despite
the prescription of high-intensity treatment having had
compliance checked, alternative diagnoses excluded, co-
morbidities treated and trigger factors removed. They
can often only maintain adequate control when taking
systemic corticosteroids and as a result are at risk of ser-
ious adverse effects.
The prevalence of severe refractory asthma has previ-
ously been estimated to be around 5 % to 10 % of the
total asthmatic population [12–14], but a more reliable
recent accurate estimate puts it at around 4 % [15]. This
is still a substantial number of patients: approximately 8
million worldwide if the estimates of prevalence are
correct.
Tiotropium is an effective long-acting muscarinic an-
tagonist (LAMA) bronchodilator that has been used in
them management of COPD for over 10 years. This
review discusses recent evidence about its efficacy and
safety in asthma and discusses its role in clinical
practice.
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The role of bronchodilators in asthma
The paradigm changing Formoterol and Corticosteroids
Establishing Therapy (FACET) study showed that adding
a long-acting bronchodilator to low dose inhaled ste-
roids was more effective at achieving control than in-
creasing the dose of ICS [16]. This led to a fundamental
change in the stepwise approach to asthma manage-
ment: recognizing the importance of effective broncho-
dilator therapy in achieving control. Subsequent studies
have shown that LABA/ICS can achieve well-controlled
asthma in around 70 % of patients but not all [17].
Over time, LABA therapy loses some of its efficacy, as
a result of tachyphylaxis [18]. There is a small reduction
in maximal bronchodilator effect, but more importantly
a loss of bronchoprotection (i.e., suppression of induced
bronchospasm) against inhaled methacholine or hista-
mine [19]. This tachyphylaxis also leads to some loss of
responsiveness to short-acting beta agonist reliever ther-
apy [20, 21]. As a result of these findings, the US Food
and Drug Administration (FDA) recommended that
LABA should not be given for long term therapy even in
combination with ICS, and that where possible patients
should step down to ICS alone [22]. There was, there-
fore, a clear need for alternative therapies.
Given the concerns about beta agonists and the fact
that patients remain uncontrolled despite LABA/ICS
therapy there has been renewed interest in the use of an-
ticholinergics. Anticholinergic bronchodilators are the
oldest documented therapy for asthma [23]. Short acting
muscarinic antagonists (SAMA) such as ipratropium
have been widely used for many years and are effective
in the management of acute severe asthma [24, 25].
However, they appear less effective in stable disease
where they seem to add little additional bronchodilata-
tion to regular short-acting beta agonists (SABA) or
LABA [26–28].
The lack of benefit from SAMA was thought to be
due to the fact that cholinergic tone had a small role
in determining airway caliber in stable asthma. How-
ever evidence on the efficacy of tiotropium has sug-
gested that this is not the case and that cholinergic
activity is responsible for increased bronchial smooth
muscle tone.
Mechanisms of action of LAMA
Acetylcholine is synthesized from choline and acetyl-CoA
mainly by the enzyme choline acetyltransferase which is
expressed in parasympathetic neurons in the airways but
also in airway epithelial cells [29–31]. Non-neuronal acetyl-
choline released from epithelial cells acts a paracrine/
autocrine hormone maintaining cellular homeostasis
and epithelial repair, regulating ciliary activity and muco-
ciliary clearance and modulating the activity of inflamma-
tory cells [32]. Acetylcholine exerts a pro-inflammatory
effect by attracting inflammatory cells and promoting their
survival and cytokine release [30].
Human airways contain M1, M2, and M3 muscarinic
receptors [33]. M3 receptors mediate acetylcholine’s
effects on airway smooth muscle tone and mucous se-
cretion from mucosal glands. M2 receptors have an in-
hibitory auto-regulatory effect on the release of
acetylcholine from both pre- and post-ganglionic nerve
terminals but are also widely expressed by other cells
such as fibroblasts and smooth muscle cells [34]. In al-
lergic asthma eosinophil-derived major basic protein acts
as an allosteric antagonist of the M2 receptor, leading to
inhibition of the auto-inhibition of acetylcholine release.
M1 receptors are expressed on post-ganglionic nerves in
the ganglia and by airway epithelial cells, where they have
a modulatory role in electrolyte and water secretion.
Both neuronal and non-neuronal acetylcholine regu-
late inflammation and remodeling via direct effects on
M3 receptors airway cells, but also indirectly as a result
of mechanical stress induced in the epithelium as a re-
sult of compression due to bronchoconstriction.
Tiotropium has a higher selectivity for M3 receptors
than for M2 receptors, and dissociates more slowly from
M3 receptors than from M2 receptors [35]. It’s effect on
airflow obstruction is mediated by its antagonism of M3
receptors leading to airway smooth muscle relaxation. It
also appears to have anti-inflammatory properties which
are also due to M3 antagonism. In animal models pre-
treatment with tiotropium reduces eosinophilic inflamma-
tion in response to allergen exposure and partly prevents
aspects of airway remodeling, inhibiting mucus gland
hypertrophy and decreasing the number of MUC5AC-
positive goblet cells, as well as reducing airway smooth
muscle thickening [36, 37]. In animal models, tiotropium
inhibits neutrophil chemotactic activity, and decreases
levels of cytokines (IL-4, IL-5, IL-13 & TNF-α) and leuko-
triene B4 in bronchoalveolar lavage fluid [38, 39].
Trials of tiotropium in asthma
Early studies
The effects of tiotropium in asthma were first explored
over 20 years ago when the sustained bronchodilator
effects and protective effects against methacholine
challenge were shown [40]. Single doses of tiotropium
caused sustained increases of approximately 10 % in
forced expiratory volume in 1 s (FEV1) in people with
baseline FEV1 values of at least 80 % predicted. The
bronchoprotector effect was sustained for at least 48 h.
A small study subsequently in patients with severe
asthma treated with salmeterol and ICS showed that
adding tiotropium and halving the dose of ICS led to
an improvement in lung function with no change in
mini-Asthma Quality of Life Questionnaire (AQLQ)
scores [41].
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The National Heart, Lung, and Blood Institute Asthma
Clinical Research Network (ACRN) in the USA under-
took a study similar to the FACET study to investigate
the effects of adding tiotropium to an inhaled gluco-
corticoid, compared to doubling of the dose of the in-
haled glucocorticoid or adding the LABA salmeterol
[42]. The patients were non-smokers (<10 pack years)
with a history of asthma confirmed by bronchodilator
reversibility or bronchial hyper-responsiveness, and an
FEV1 > 40 % predicted. During the 4 week run-in phase
all patients were treated with beclomethasone 80 μg
twice daily. If patients had an FEV1 < 70 % predicted at
the end of the run-in they were randomised to have tio-
tropium 18 μg from the Handihaler device every morn-
ing or salmeterol 50μg twice daily added or to receive
beclomethasone 160 μg twice daily for 14 weeks. The
study was double blind and placebo controlled.
Two hundred ten patients were enrolled. Tiotropium
improved lung function and symptom control compared
with doubling the ICS dose (mean difference between
tiotropium and doubling the ICS dose in morning peak
expiratory flow (PEF): 25.8 L/min, p < 0.001; evening
PEF: 35.3 L/min, p < 0.001; pre-bronchodilator FEV1:
0.10 L, p = 0.004; seven-question ACQ (ACQ-7): −0.18,
p = 0.02). Tiotropium was non-inferior to salmeterol for
all outcomes but increased the pre-bronchodilator FEV1
more than did salmeterol, with a difference of 0.11 L
(P = 0.003). A subsequent analysis showed that although
approximately equal numbers of patients showed a
positive response in PEF and asthma control days to
tiotropium and salmeterol, more showed a positive re-
sponse in FEV1 with tiotropium [43]. This analysis also
showed that a positive lung function response to tiotro-
pium (in both FEV1 and morning PEF) was apparent in
patients with higher cholinergic tone, indicated by a lower
resting heart rate, and increased airway obstruction.
A proof of concept study investigated the efficacy and
safety of added tiotropium in inadequately controlled
asthmatic patients (Asthma Control Questionnaire (ACQ)
score >1.5 and post-bronchodilator FEV1 < 80 % of pre-
dicted) despite treatment with at least high-dose ICS plus
LABA (GINA step 4–5). 107 patients were randomized in
this double-blind, placebo-controlled, crossover study
comprising three 8–week treatment periods. All patients
received 5 or 10 μg of tiotropium or matching placebo ad-
ministered once daily in the morning through the Respi-
mat soft mist inhaler, in a random sequence. Both doses
of tiotropium significantly increased peak FEV1 compared
to placebo (5 μg difference, 0.139 L; 95 % CI, 0.096–0.181
L; 10 μg difference, 0.170 L; 95 % CI, 0.128–0.213 L) with
no significant difference between the active doses. Other
lung function secondary end points responses were con-
sistent with the primary end point results: both doses of
tiotropium increased the trough FEV1 at the end of the
dosing interval (5 μg: 0.086 L [95 % CI, 0.041–0.132 L]; 10
μg: 0.113 mL [95 % CI, 0.067–0.159 mL]; both P < .0004)
and daily home peak expiratory flow measurements were
higher with both tiotropium doses. Both doses had sus-
tained effects on FEV1 compared to placebo over a 24 h
period in a subgroup of patients in whom this was
assessed. There were only small and non-significant differ-
ences in rescue medication use among the 3 periods, and
minimal not significant changes in mini–AQLQ scores
over the entire treatment period of 0.1 points for both ac-
tive treatments compared with placebo and no significant
differences in the symptom scores measured with an elec-
tronic diary. Subgroup analyses based on sex, FEV1% pre-
dicted or reversibility at screening, smoking status, or
asthma duration showed that the effects of both doses of
tiotropium compared with placebo were not significantly
affected by these factors. The incidence of adverse events
was comparable between treatment groups, although dry
mouth occurred at a higher incidence in patients treated
with tiotropium 10 μg (7 % v 2 % with tiotropium 5 μg
and 1 % with placebo).
A second proof of concept study examined the effect of
tiotropium compared to salmeterol in 388 patients with
B16-Arg/Arg beta-2 receptor polymorphism and moder-
ate symptomatic asthma despite maintenance therapy
with 400–1000 μg of budesonide or equivalent per day
[44]. At the time these patients were thought to be less re-
sponsive to LABAs but the B16-Arg/Arg phenotype has
subsequently been shown to have no influence on re-
sponses to salmeterol therapy in asthmatic patients.
During the run-in period all patients were treated with
salmeterol 50 μg twice-daily via a metered-dose inhaler.
They were then randomised to 16 weeks of treatment
with tiotropium 5 mg via Respimat once daily in the
evening, to continue salmeterol 50 μg twice daily, or pla-
cebo, whilst continuing their ICS. Mean weekly morning
pre-dose PEF was maintained during the treatment
period with tiotropium and salmeterol but decreased in
patients switched to placebo. Tiotropium was non-inferior
to salmeterol. The overall incidences and patterns of ad-
verse events were similar across all groups.
The optimal treatment tiotropium regime in asthma
was examined in two phase II studies. The first was a 4
week, 4 way cross over dose ranging study of tiotropium
5, 2.5 and 1.25 μg and placebo via the Respimat once-
daily in the evening as an add-on to medium-dose ICS
in 149 adults with moderate asthma [45]. Statistically
significant improvements in peak FEV1 (0–3h) response
and ACQ-7 scores were observed with each tiotropium
dose compared with placebo. The largest improvements
were with the 5 μg dose. Adverse events were compar-
able between treatment groups.
The second study compared once daily dosing with
5μg tiotropium in the evening with twice daily dosing
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with 2.5μg tiotropium in 94 adults with moderate
asthma treated with moderate dose ICS (400–800 μg of
budesonide or equivalent per day) over 4 weeks in a
crossover study [46]. Both once-daily 5 μg and twice-
daily 2.5 μg regimes provided significant and comparable
24-h bronchodilation (once-daily 5 μg, 0.158 L compared
with placebo; twice-daily 2.5 μg, 0.149 L (both p < 0.01)),
and similar improvements in peak FEV1, trough FEV1,
and morning and evening PEF. Adverse events were again
comparable between all treatment regimens.
Phase III studies in adults
The longer term efficacy of once daily tiotropium as
add-on to at least ICS maintenance therapy in adult pa-
tients across all severities of symptomatic asthma has
been investigated in five phase III double-blind, placebo-
controlled, parallel-group trials. The two identical Pri-
moTinA trials investigated the effects of tiotropium 5 μg
or placebo as an add-on to high-dose ICS (≥800 μg
budesonide or the equivalent) plus a LABA over 48
weeks in 912 patients with severe symptomatic asthma
[47]. All patients had an ACQ-7 score ≥ 1.5, a post-
bronchodilator FEV1 ≤ 80 % predicted value and FEV1/
FVC ≤ 70 % and had had at least one exacerbation that
was treated with systemic glucocorticoids in the previous
year. They were also either lifelong non-smokers or to
have a smoking history of fewer than 10 pack-years, with
no smoking in the year before the study. Tiotropium
significantly improved peak FEV1 by a mean 0.110 L
(p < 0.0001) and trough FEV1 by a mean of 0.093 L
(p < 0.0001) and increased the time to both the first
severe asthma exacerbation (hazard ratio 0.79, p = 0.03)
and the first episode of asthma worsening (hazard ratio
0.69, p < 0.001). Improvements in asthma control and
quality of life were also observed in both trials with
marked improvements in the placebo groups particularly
in trial 1. At week 24, the mean difference in ACQ-7
scores and AQLQ score between groups was only statisti-
cally significant in trial 2 but did not exceed the minimal
clinically important differences for the ACQ-7 of 0.5 [48]
or AQLQ of 0.5 [49]. The incidence of adverse events was
comparable between treatment groups.
Pre-specified post hoc subgroup analysis showed that
the improvements in peak FEV1 in the tiotropium
tended to be higher in patients with a lower FEV1 and
in ex-smokers, but were not related to level of reversibil-
ity, age, body-mass index, allergic status, asthma dur-
ation, ACQ-7 score at baseline, or prior use of systemic
glucocorticoids.
A further two replicate, double-dummy trials have ex-
amined the effects of tiotropium in 2103 patients with
moderate symptomatic asthma (ACQ-7 score ≥ 1.5) and
persistent airflow obstruction (post-bronchodilator FEV1
60–90 %) despite treatment with medium-dose ICS
(≥800 μg of budesonide or the equivalent) [50]. Patients
received once-daily tiotropium 5 or 2.5 μg, twice-daily
salmeterol 50 μg, or matching placebo for 24 weeks.
Both doses of tiotropium significantly improved lung
function compared with placebo (pooled effect in peak
FEV1 0.185 L (95 % CI 0.146–0.223 L; p < 0.0001)
with 5 μg; 0.223 L (95 % CI 0.185–0.262 L; p < 0.0001)
with 2.5 μg), with the improvements in peak FEV1 main-
tained over 24 h. Both doses also led to significant im-
provements in asthma control, as assessed by ACQ-7
responder rate (5 μg: OR 1.32, 95 % CI 1.02–1.71,
p = 0.035; 2.5 μg: OR 1.33, 95 % CI 1.03–1.72, p = 0.031),
and the risk of first severe asthma exacerbation or first
episode of asthma worsening was reduced with tiotropium
add-on therapy. The effects of tiotropium were similar to
those of salmeterol which increased peak FEV1 by 0.196 L
(95 % CI 0.158–0.234 L; p < 0.0001) and increased the pro-
portion showing an ACQ response (OR 1.46, 95 % CI
1.13–1.89, p = 0.0039). The incidence of adverse events
was similar across all treatment groups.
To complete the phase III programme in adults a fur-
ther trial examined the effect of tiotropium in adults
with symptomatic asthma (ACQ-7 score ≥ 1.5) and per-
sistent airflow obstruction (post-bronchodilator FEV1
60-90 %) on low- to medium dose ICS (200–400 μg of
budesonide or the equivalent) therapy [51]. 464 patients
were randomised to 12 weeks treatment with 2.5 μg or 5
μg tiotropium or placebo once daily in the evening via
Respimat. Both doses of tiotropium improved peak
FEV1 (0–3h) compared to placebo (adjusted mean dif-
ference 0.128 L 95 % CI 0.057–0.199 L, p < 0.001 for 5
μg; 0.159 L 95 % CI 0.088–0.230 L, p < 0.001 for 2.5 μg).
Both doses also improved the secondary endpoints of
trough FEV1 and FEV1 area under the curve (0–3h),
and morning and evening PEF compared to placebo.
The incidence of adverse events was similar across all
treatment groups.
A one year safety study of tiotropium in asthma has
been carried out in Japan [52]. 285 patients were rando-
mised to receive 2.5 μg or 5 μg tiotropium or placebo
once daily in addition to LABA/ICS. There was no sig-
nificant difference in adverse events between the groups.
Phase III studies in adolescents and children
Following on from the studies in adults, studies of the
effects of tiotropium in adolescents and children with
asthma have been undertaken. Phase II studies in adoles-
cents showed similar effects on lung function when tio-
tropium is added to LABA/ICS as those seen in adults
[53, 54]. A 48 week phase III study investigated the effects
of adding 2.5 μg or 5 μg tiotropium or placebo once daily
in 398 adolescents (age 12–17) with symptomatic asthma
(ACQ-7 score ≥ 1.5) and a pre-bronchodilator FEV1
60–90 %, despite therapy with ICS with or without a
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LABA or leukotriene receptor antagonist (LTRA) [55].
Peak FEV1(0–3h) was statistically significantly greater
with both doses of tiotropium (0.174 L 95 % CI
0.076–0.272 L, p < 0.001 for 5 μg; 0.134 L 95 % CI
0.034–0.234 L, p < 0.01 for 2.5 μg) and trough FEV1
was also statistically significantly improved by 5 μg
(0.117 L 95 % CI 0.010–0.223 L, p < 0.03) but not by
2.5 μg. Weekly mean morning and evening PEF were
also improved and there was a trend for an improve-
ment in asthma control and quality of life.
A 12 week study in China compared ICS to ICS plus
tiotropium in 80 children aged 6–14 with newly diag-
nosed moderate persistent asthma [56]. Compared with
baseline, FEV1, FVC and PEF were significantly im-
proved in both groups at 4, 8, and 12 weeks (P < 0.01)
with significantly larger improvements in the tiotropium
group compared with the control group (P < 0.05). Res-
cue medication use and night time waking were signifi-
cantly reduced in the tiotropium group compared to the
control group (P < 0.05; P < 0.001 respectively). Further
studies in adolescents, children aged 6-11 and infants
aged 1-5 have been completed.
Real world studies and health economic analyses
Although unlicensed, long-acting anti-muscarinics have
been prescribed for the treatment of asthma in the
United Kingdom (UK) since 2002, predominantly as an
add-on therapy in older patients with poorly controlled
asthma despite good treatment compliance and usually
on the recommendation of specialists. A retrospective
study of data from a UK primary care database on 2042
adults prescribed tiotropium with a diagnosis of asthma
but no diagnosis of chronic obstructive pulmonary disease
(COPD) patients showed that in the 12 months after the
addition of tiotropium compared to the pervious 12
months there was a significant decrease in the number of
people having exacerbations (26.6 % v 36.8 %, p < 0.001)
and course of oral steroids (25.5 % v 35.8 %, P < 0.001),
and a significant increase in the number of people with
controlled asthma (52.4 % v 41.4 % p < 0.001) [57].
An economic model has been developed to look at the
cost-effectiveness of tiotropium add-on therapy, from the
perspective of the UK National Health Service [58]. Using
data from the paired PrimoTinA trials [47] this model
found that in patients with severe symptomatic asthma des-
pite treatment with high-dose ICS plus LABA, add-on
tiotropium therapy was cost effective. It generated an incre-
mental 0.24 quality adjusted life years (QALY) and £5,238
costs over a lifetime horizon, resulting in an incremental
cost-effectiveness ratio of £21,906 per QALY gained.
What does this mean for clinical practice ?
These trials in adults show the efficacy and safety of tio-
tropium in people with mild to moderate asthma when
it was added to ICS and in people with severe asthma
when it was added to high doses of ICS plus LABA, as
well as in adolescents. Early studies of other LAMAs
(glycopyrrolate and umeclidinium) in asthma have been
published [59, 60], but tiotropium is currently the only
LAMA licenced for use in asthma.
Adding tiotropium to ICS in people with uncontrolled
mild to moderate asthma is safe and effective and the ef-
ficacy of tiotropium is similar to that of salmeterol. In
time adding a LAMA may become the recommended
option given the concerns about tachyphylaxis to LABAs
but the lack of a combination inhaler containing both a
LAMA and an ICS may limit the uptake of this ap-
proach as there would be real concerns that patients
may omit the ICS and rely on the symptomatic benefit
of the LAMA leaving them at significant risk of exacer-
bations and even death as was seen when LABA inhalers
were first introduced [61, 62].
The biggest unmet need is in people with uncontrolled
asthma despite treatment with ICS (whether medium or
high dose) plus LABA. In this group tiotropium signifi-
cantly improved lung function and reduced the frequency
of exacerbations [47]. The effect is not dependent on the
asthma phenotype and appears cost effective, making this
a clinically very useful option for these patients. Real
world data confirms the efficacy of tiotropium in asthma
beyond the constraints of a randomised clinical trial. On
the basis of this evidence the GINA report now recom-
mends tiotropium as an add on therapy at steps 4 and 5
[4], and as more evidence emerges and experience grows
it may become the preferred option.
Conclusions
Tiotropium appears to be safe, effective and cost effect-
ive in people with uncontrolled severe asthma when
added to high doses of ICS plus LABA. This group of
patients has the biggest unmet need for additional ther-
apy and tiotropium appears equally effective in all phe-
notypes. Tiotropium is also safe and effective in adults
with mild to moderate asthma when added to ICS, and
in adolescents. Data from on-going studies will clarify its
role in children. It is currently the only LAMA licenced
for use in asthma and is now recommended as an add
on therapy at steps 4 and 5 in the GINA report.
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